2. Signaling Pathways
  3. Cytoskeleton
  4. Annexin A
  5. Annexin A Inhibitor

Annexin A Inhibitor

Annexin A Isoform Comparison

Annexin A Inhibitors (10):

Cat. No. Product Name Effect Purity
  • HY-101200
    Linsidomine hydrochloride
    		Inhibitor 99.97%
    Linsidomine hydrochloride (SIN-1 chloride) is a spontaneous ROS/RNS generator and peroxynitrite donor. Linsidomine hydrochloride is a vasodilator and platelet aggregation inhibitor. Linsidomine hydrochloride induces oxidative stress-induced chondrocyte apoptosis and necrosis. Linsidomine hydrochloride inhibits the migration, proliferation and neointima formation of vascular smooth muscle cells by inhibiting the expression of annexin A2. In addition, low doses of Linsidomine hydrochloride shows protective effects on Zn2+ treated nerve cells.
  • HY-136465
    A2ti-1
    		Inhibitor 99.78%
    A2ti-1 is a selective and high-affinity annexin A2/S100A10 heterotetramer (A2t) inhibitor with an IC50 of 24 μM. A2ti-1 specifically disrupts the protein-protein interaction (PPI) between A2 and S100A10. A2ti-1 prevents human papillomavirus type 16 (HPV16) infection.
  • HY-P992100
    Amesotatug
    		Inhibitor
    Amesotatug is a humanized monoclonal antibody and ANXA1 binder. Amesotatug binds to Homo sapiens ANXA1 and exhibits antineoplastic activity. Amesotatug can be used for the research of cancer.
  • HY-16254
    Hydrocortamate hydrochloride
    		Inhibitor
    Hydrocortamate hydrochloride is a broad-spectrum immunosuppressant. Hydrocortamate hydrochloride has been identified as a potential inhibitor of T cell proliferation in ischemia-reperfusion injury (IRI), specifically targeting the ANXA1 gene. Hydrocortamate hydrochloride can be used in inflammation research.
  • HY-P2333
    LCKLSL
    		Inhibitor 99.26%
    LCKLSL is a N-terminal hexapeptide and a competitive annexin A2 (AnxA2) inhibitor. LCKLSL potently inhibits the binding of tissue plasminogen activator (tPA) to AnxA2. LCKLSL also inhibits the generation of plasmin and has anti-angiogenic roles.
  • HY-P2333A
    LCKLSL hydrochloride
    		Inhibitor 98.05%
    LCKLSL hydrochloride is a N-terminal hexapeptide and a competitive annexin A2 (AnxA2) inhibitor. LCKLSL hydrochloride potently inhibits the binding of tissue plasminogen activator (tPA) to AnxA2. LCKLSL hydrochloride also inhibits the generation of plasmin and has anti-angiogenic roles.
  • HY-136466
    A2ti-2
    		Inhibitor 99.80%
    A2ti-2 is a selective and low-affinity annexin A2/S100A10 heterotetramer (A2t) inhibitor with an IC50 of 230 μM. A2ti-2 specifically disrupts the protein-protein interaction (PPI) between A2 and S100A10. A2ti-2 prevents human papillomavirus type 16 (HPV16) infection.
  • HY-125355
    SEC
    		Inhibitor 98.26%
    SEC induces activation of ANXA7 GTPase via the AMPK/mTORC1/STAT3 signaling pathway. SEC selectively promotes apoptosis in cancer cells, expressing a high level of ITGB4 by inducing ITGB4 nuclear translocation.
  • HY-169212
    I194496
    		Inhibitor 98.52%
    I194496 is a potent cystathionine γ-lyase (CSE) inhibitor, with an IC50 of 0.79 mM. I194496 can inhibit the growth of human TNBC cells via the dual targeting PI3K/Akt and Ras/Raf/ERK pathway and suppress the metastasis of human TNBC cells via down-regulating Anxa2/STAT3 and VEGF/FAK/Paxillin signaling pathways.
  • HY-101200R
    Linsidomine hydrochloride (Standard)
    		Inhibitor
    Linsidomine (hydrochloride) (Standard) is the analytical standard of Linsidomine (hydrochloride). This product is intended for research and analytical applications. Linsidomine hydrochloride (SIN-1 chloride) is a spontaneous ROS/RNS generator and peroxynitrite donor. Linsidomine hydrochloride is a vasodilator and platelet aggregation inhibitor. Linsidomine hydrochloride induces oxidative stress-induced chondrocyte apoptosis and necrosis. Linsidomine hydrochloride inhibits the migration, proliferation and neointima formation of vascular smooth muscle cells by inhibiting the expression of annexin A2. In addition, low doses of Linsidomine hydrochloride shows protective effects on Zn2+ treated nerve cells.